Protalix Biotherapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Protalix Biotherapeutics, Inc. on December 13, 2018, reporting on the 2018 Special Meeting of Stockholders held on that date in Tel Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance proceedings.
Material Changes
The primary material event reported is the adjournment of the 2018 Special Meeting of Stockholders. The meeting was postponed to January 10, 2019, at 1:00 p.m. Israel time, to allow the Company additional time to solicit proxies from stockholders.
Outlook, Risks, and Management Commentary
Management indicated that the adjournment was necessary to facilitate further proxy solicitation. The record date for the meeting remains October 15, 2018. The adjournment was approved by a vote of 85,927,688 shares of common stock, with no shares voting against or abstaining.
Key Facts for Investor Verification
- The Special Meeting was adjourned to January 10, 2019.
- The adjournment received unanimous approval from shares present (85,927,688 shares).
- The record date for voting remains October 15, 2018.
- The purpose of the adjournment was to solicit additional proxies.
- No financial performance data is included in this specific filing.